Worldwide guidelines for respiratory tract infections: community-acquired pneumonia (Q34382815)

1 August 2017

1 reference

title

Worldwide guidelines for respiratory tract infections: community-acquired pneumonia (English)

1 reference

1 August 2017

1 reference

Dalhoff K

1

1 reference

1 August 2017

1 January 2001

1 reference

International Journal of Antimicrobial Agents

1 August 2017

1 reference

1 August 2017

18 Suppl 1

1 reference

1 August 2017

S39-44

1 reference

[The diagnosis and treatment of community-acquired pneumonia. SEPAR. Sociedad Española de Neumología y Cirugía Torácica]

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Antimicrobial treatment of community acquired pneumonia in adults: A conference report

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Society

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

WHO warns of threat of "superbugs".

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Community acquired pneumonia: aetiology and usefulness of severity criteria on admission

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Diagnosis of ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Community-acquired pneumonia. Tailoring management of adult patients according to risk category

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Excessive accumulation of mucus in children with asthma: a potential role for erythromycin? A case discussion

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900405-8

7 January 2021

10.1016/S0924-8579(01)00405-8

Identifiers

DOI

1 reference

release_egmkqz5pufdkjere3viduy7liq

1 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/egmkqz5pufdkjere3viduy7liq

24 November 2022

mapped directly with Wikidata item

PubMed ID

11574194

1 reference

PubMed ID

11574194